CRC patients with BRAF V600E mutation have a median OS of nearly 11 months, are chemotherapy insensitive, have an extremely poor prognosis, and are poorly treated with standard chemotherapy (Cremolini et al., 2015). Here, BRAF is linked to colorectal carcinoma.